semaglutide china price China's weight-loss drug makers take on global giants as Novo Nordisk patent expires Novo Nordisk braces for generic

This weekly injection not only aids in weight loss but also helps maintain it

Managing Common Side Effects All medications have side effects, and GLP-1 receptor agonists are no exception

According to the MHRA-approved SmPC, nausea is classified as 'very common' (affecting more than 1 in 10 people), whilst other gastrointestinal symptoms such as vomiting, diarrhoea, and abdominal discomfort are listed as 'common' (affecting up to 1 in 10 people)

The following table showcases the mean weight loss observed in clinical trials investigating Tesofensine and a commonly prescribed GLP-1 agonist, Semaglutide, in obese adults without diabetes: It's crucial to acknowledge that these results are specific to the studies cited and may not be generalizable to all individuals